Innovent Expands Global Phase 3 Study in Immunotherapy-Resistant NSCLC to Include Non-Squamous Patients #China #Suzhou #Innovent_Biologics #IBI363 #TAK-928
@newsen.bsky.socialExplore
@newsen.bsky.social
@newsen.bsky.socialInnovent Expands Global Phase 3 Study in Immunotherapy-Resistant NSCLC to Include Non-Squamous Patients #China #Suzhou #Innovent_Biologics #IBI363 #TAK-928